Indication
Malignant hyperthermia
Malignant hyperthermia is a rare, life-threatening pharmacogenetic disorder of skeletal muscle characterized by a fulminant hypermetabolic state triggered primarily by volatile inhalational anesthetics or the depolarizing neuromuscular blocker succinylcholine. Read more about Malignant hyperthermia
18 drugs 15 manufacturers
Drugs that treat it
Common Malignant hyperthermia therapies.
DANTRIUM (dantrolene sodium)
DANTROLENE SODIUM
REVONTO (dantrolene sodium)
DANTROLENE SODIUM
DANTRIUM (dantrolene sodium)
DANTRIUM (dantrolene sodium)
DANTROLENE SODIUM
DANTROLENE (dantrolene sodium)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMalignant hyperthermia is a rare, life-threatening pharmacogenetic disorder of skeletal muscle characterized by a fulminant hypermetabolic state triggered primarily by volatile inhalational anesthetics or the depolarizing neuromuscular blocker succinylcholine.
Primarily affecting genetically susceptible pediatric and adult surgical patients—most often carrying mutations in the ryanodine receptor gene (*RYR1*)—the condition results from uncontrolled intracellular calcium release from the sarcoplasmic reticulum.
This sustained calcium overload drives continuous skeletal muscle contraction, marked glycogenolysis, and profound cellular metabolism, clinically producing refractory hypercapnia, generalized muscle rigidity, tachycardia, severe metabolic and respiratory acidosis, rapid core hyperthermia, and acute rhabdomyolysis.
- nih.gov
Malignant hyperthermia is a rare, life-threatening pharmacogenetic disorder of skeletal muscle characterized by a fulminant hypermetabolic state triggered primarily by volatile inhalational anesthetics or the depolarizing neuromuscular blocker succinylcholine This sustained calcium overload drives continuous skeletal muscle contraction, marked glycogenolysis, and profound cellular metabolism, clinically producing refractory hypercapnia, generalized muscle rigidity, tachycardia, severe metabolic ...
- nih.gov
Malignant hyperthermia is a rare, life-threatening pharmacogenetic disorder of skeletal muscle characterized by a fulminant hypermetabolic state triggered primarily by volatile inhalational anesthetics or the depolarizing neuromuscular blocker succinylcholine
- nih.gov
Primarily affecting genetically susceptible pediatric and adult surgical patients—most often carrying mutations in the ryanodine receptor gene (*RYR1*)—the condition results from uncontrolled intracellular calcium release from the sarcoplasmic reticulum This sustained calcium overload drives continuous skeletal muscle contraction, marked glycogenolysis, and profound cellular metabolism, clinically producing refractory hypercapnia, generalized muscle rigidity, tachycardia, severe metabolic and re...
- nih.gov
Primarily affecting genetically susceptible pediatric and adult surgical patients—most often carrying mutations in the ryanodine receptor gene (*RYR1*)—the condition results from uncontrolled intracellular calcium release from the sarcoplasmic reticulum
- nih.gov
Primarily affecting genetically susceptible pediatric and adult surgical patients—most often carrying mutations in the ryanodine receptor gene (*RYR1*)—the condition results from uncontrolled intracellular calcium release from the sarcoplasmic reticulum
Personalize your experience
Follow Malignant hyperthermia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.